Assessment of the neutrophil dominating protein calprotectin in feces: a methodologic study

AG Røseth, MK Fagerhol, E Aadland… - Scandinavian journal …, 1992 - Taylor & Francis
This study describes methods for extraction and quantification of calprotectin (LI protein) in
feces by enzyme immunoassay. This protein is a prominent antimicrobial component of …

Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease

JA Tibble, G Sigthorsson, S Bridger, MK Fagerhol… - Gastroenterology, 2000 - Elsevier
Background & Aims: Prediction of relapse of inflammatory bowel disease has important
implications for therapeutic stategies. We assessed whether measurement of intestinal …

Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin

M Steinbakk, CF Naess-Andresen, MK Fagerhol… - The Lancet, 1990 - Elsevier
The calcium binding L1 protein was found to inhibit growth of blood culture isolates of
Candidaspp and cerebrospinal fluid isolates of Cryptococcus neoformans. Minimum inhibitory …

Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease

…, PN Schmidt, MK Fagerhol - Scandinavian journal of …, 1999 - Taylor & Francis
Background: Several studies have suggested that clinical indices of disease activity in
inflammatory bowel disease (IBD) do not adequately reflect the degree of inflammation in most …

[HTML][HTML] Functional and clinical aspects of the myelomonocyte protein calprotectin.

B Johne, MK Fagerhol, T Lyberg, H Prydz… - Molecular …, 1997 - ncbi.nlm.nih.gov
Calprotectin is a calcium binding heterocomplex protein consisting of two heavy and one
light chain.'2 It belongs to the S-100 protein family and is derived predominantly from …

High prevalence of NSAID enteropathy as shown by a simple faecal test

…, G Sigthorsson, R Foster, D Scott, MK Fagerhol… - Gut, 1999 - gut.bmj.com
BACKGROUND The diagnosis of non-steroidal anti-inflammatory drug (NSAID) induced
enteropathy is difficult, requiring enteroscopy or the use of four day faecal excretion of 111 In …

Purification and partial characterization of a highly immunogenic human leukocyte protein, the L1 antigen

I Dale, MK Fagerhol, I Naesgaard - European Journal of …, 1983 - Wiley Online Library
… of L1 in granulocytes (2-5 pg/cell) has later been confirmed by immunohistochemical studies
which have also verified that L1 is found in monocytes (Dale, Brandtzaeg and Fagerhol, …

Release and quantitation of a leucocyte derived protein (L1)

MK Fagerhol, I Dale, T Anderson - Scandinavian Journal of …, 1980 - Wiley Online Library
… of the protein will be published in a separate report (Dale & Fagerhol, in preparation). …
been estimated to about 51000 daltons (Dale & Fagerhol, in preparation). Since the total protein …

Bowel inflammation as measured by fecal calprotectin: a link between lifestyle factors and colorectal cancer risk

A Poullis, R Foster, A Shetty, MK Fagerhol… - … Biomarkers & Prevention, 2004 - AACR
The mechanisms by which the lifestyle risk factors obesity, physical inactivity, and low fiber
intake predispose to colorectal cancer (CRC) are unclear. Chronic bowel inflammation …

Distribution of a new myelomonocytic antigen (L1) in human peripheral blood leukocytes: immunofluorescence and immunoperoxidase staining features in …

I Dale, P Brandtzaeg, MK Fagerhol… - American journal of …, 1985 - academic.oup.com
… Brandtzaeg P, Dale I, Fagerhol MK: Tissue distribution of a new human myelomonocytic
antigen (LI). Comparison with other cell marker antigens by paired immunofluorescence staining…